Appili Therapeutics Announces Closing of Public Offering of C$10.25M
February 20, 2020
10.25 Million CAD
On February 20, 2020, Appili Therapeutics Inc. ("Appili" or the "Company") completed the closing of its previously announced public offering of units. The Offering was made pursuant to an agency agreement entered into between Bloom Burton Securities Inc. (the “Lead Agent”), Mackie Research Capital Corporation, Haywood Securities Inc. and Industrial Alliance Securities Inc. (together with the Lead Agent, the “Agents”) and the Company.
Appili issued a total of 12,812,500 Units at a price of $0.80 per Unit for aggregate gross proceeds of $10,250,000. Each Unit is comprised of one Class A common share of the Company and one-half of one Common Share purchase warrant of the Company. Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price of CDN$1.10 per Warrant Share until February 20, 2023.
Bloom Burton is an investment services and advisement firm focused exclusively on the medical and life science industry.
Appili Therapeutics Inc. was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this critical disease space.
McCarthy Tétrault LLP advised Bloom Burton, as Lead Agent, with a team led by Myreille Gilbert that included Philippe Leclerc, Sonia Struthers, David Martin (Securities), Véronique Wattiez Larose (Intellectual Property), Marie-Soleil Landry and Quentin Lageix (Tax).